These findings, from the APTneo trial (ClinicalTrials.gov Identifier: NCT03595592), were presented at the San Antonio Breast Cancer Symposium 2023.
News
- Neoadjuvant Treatment Combos Face Off in HER2+ Breast Cancer
- Some breast cancer survivors may safely de-escalate mammography three years after surgery
Biomedical technology · Cardiology · Dentistry · Diabetes · Diseases ... San Antonio Breast Cancer Symposium, held December 5–9, 2023. Both U.S. ...
- Bluebird bio's sickle-cell disease treatment nets FDA approval - Boston Business Journal
San Antonio · San Francisco · Seattle · Silicon Valley · St. Louis · Tampa Bay ... Biotech led by ex-Novartis exec brings in $90M for cancer drugs.
- Pregnancy After Breast Cancer Treatment Is Not Contraindicated in BRCA Carriers
... San Antonio Breast Cancer Symposium 2023. The study results provide ... Disclosures: Some study authors declared affiliations with biotech, ...
- Study Shows Positive Pregnancy Outcomes for BRCA1/2-Mutant Breast Cancer Patients
A recent study presented at the San Antonio Breast Cancer Symposium 2023 has revealed reassuring findings regarding pregnancy outcomes in patients ...